Roi Avraham

Roi Avraham

Auto-generated profile, based on publicly available information

Roi Avraham

Weizmann Institute of Science

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2017 in Science
Verified
Journal Article
Closed access
PDF file
LGLeore T. Geller
Leore T. Geller
MBMichal Barzily-Rokni
Michal Barzily-Rokni
TDTal Danino
Tal Danino
OJOliver H. Jonas
Oliver H. Jonas
NSNoam Shental
Noam Shental
RSRavid Straussman
Ravid Straussman
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2′,2′-difluorodeoxycytidine) into its inactive form, 2′,2′-difluorodeoxyuridine. Metabolism was dependent on the expression of a long isoform of the bacterial enzyme cytidine deaminase (CDDL), seen primarily in Gammaproteobacteria. In a colon cancer mouse model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxacin. Gemcitabine is commonly used to treat pancreatic ductal adenocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance of these tumors. Consistent with this possibility, we found that of the 113 human PDACs that were tested, 86 (76%) were positive for bacteria, mainly Gammaproteobacteria.

21 January 2011 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
RARoi Avraham
Roi Avraham
YYYosef Yarden
Yosef Yarden

1 September 2015 in Cell
Verified
Journal Article
Closed access
RARoi Avraham
Roi Avraham
NHNathan Haseley
Nathan Haseley
DBDouglas Brown
Douglas Brown
CPCristina Penaranda
Cristina Penaranda
HJHumberto B. Jijon
Humberto B. Jijon
DHDeborah T. Hung
Deborah T. Hung

9 April 2008 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MBMarganit Benish
Marganit Benish
IBInbal Bartal
Inbal Bartal
YGYael Goldfarb
Yael Goldfarb
BLBen Levi
Ben Levi
RARoi Avraham
Roi Avraham
SBShamgar Ben-Eliyahu
Shamgar Ben-Eliyahu

1 March 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AGAriella Glasner
Ariella Glasner
RARoi Avraham
Roi Avraham
ERElla Rosenne
Ella Rosenne
MBMarganit Benish
Marganit Benish
OZOded Zmora
Oded Zmora
SBShamgar Ben-Eliyahu
Shamgar Ben-Eliyahu
Clinical practice does not consider perioperative paracrine and neuroendocrine stress responses as risk factors for cancer recurrence, although recent animal studies provided supportive evidence. Suggested mechanisms include the effects of stress-hormones on tumor cells and on host physiology. In this study, in mice undergoing primary tumor excision, we tested the survival-enhancing potential of perioperative blockade of catecholamines and prostaglandins, and studied potential mediating mechanisms. C57BL/6J mice were inoculated intrafootpad with syngeneic B16F10.9-melanoma or Lewis lung carcinoma, and the paw was amputated when a developing tumor exceeded 100 μl. The clinically used β-adrenergic antagonist propranolol, and/or the cyclooxygenase-2 inhibitor etodolac, were administered once before amputation, and recurrence-free survival was monitored. In different studies, NK cytotoxicity, leukocytes' molecular functional markers, and vascular endothelial growth factor secretion by tumor cells were studied in the context of surgery and drug treatments. The findings indicated that the combination of propranolol and etodolac, but neither drug alone, significantly and markedly improved survival rates in both tumor models, and was as effective as established immunostimulatory agents (IL-12 and polyinosinic-polycytiylic acid). Surgery markedly reduced NK cytotoxicity and NK cell expression of Fas ligand and CD11a, reduced all circulating lymphocyte-subtype concentrations, and increased corticosterone levels. Propranolol and etodolac administration counteracted these perturbations. B16 and 3LL secreted vascular endothelial growth factor in vitro, but secretion was not affected by catecholamine agonists, prostaglandins, corticosterone, propranolol, or etodolac. Overall, propranolol and etodolac administration, which could be applied perioperatively in most cancer patients with minimal risk and low cost, has counteracted several immunologic and endocrinologic perturbations and improved recurrence-free survival rates in mice undergoing primary tumor excision.

22 July 2007 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MKMenachem Katz
Menachem Katz
IAIdo Amit
Ido Amit
ACAmi Citri
Ami Citri
TSTal Shay
Tal Shay
SCSilvia Carvalho
Silvia Carvalho
YYYosef Yarden
Yosef Yarden